Ezalife
OperatingEzaLife Inc.
Biotech · Aurora, CO
Ezalife created an FDA-registered Button Huggie® medical device that helps solve a critical problem affecting over 1 million families each year, when G-buttons (feeding tubes from the stomach, to deliver fluids, nutrition and medications) are fitted in the US. We generated $8K in pre-orders, and another $11k in our 1st 30 days’ sales. Backed by Children's Hospital Colorado and led by an experienced, career, investor-appointed CEO.
Financials
FY2023–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
4 people
Dr. Moulton is the Founder of Ezalife and the inventor of the Button Huggie®. Dr. Moulton is a pediatric surgeon at Children's Hospital Colorado and Professor of Surgery at the University of Colorado School of Medicine. He has authored over 100 peer-reviewed articles, holds 8 issued and 9 pending US/EU patents.
John is a Career CEO, hired by multiple investment funds to launch and sell businesses across venture capital, family office, and private equity-backed startups. He has spearheaded successful ventures from early-stage through growth phases, from pre-revenue to scaled annual revenue growth, with considerable go-to-market success in MedTech markets, previously reaching over 2,000 hospitals and universities. His track record includes one successful turnaround to a highly profitable, high-growth company, as well as multiple lucrative secondary offerings and exits, to both private equity and strategic buyers.
As a three-time Go-To-Market leader with John, Kara has led high-performing teams and driven sustainable business growth for both B2C and B2B products at multiple successfully exited companies. She is considered a thought leader on revenue automation and GTM acceleration, with expertise in creating multichannel marketing strategies and developing effective outreach campaigns to grow strategic partnerships.
Bradley is the Vice President, Treasury at Children’s Hospital Colorado. Experienced in fast changing and high pressure environments including corporate finance, corporate restructuring, acquisition by private equity and rapid growth, he is well versed in treasury, financial analysis, long range planning, network economics and team development.
Names and titles as disclosed on StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 1 annual reports (FY2025)
Missing: 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.